• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Mologic starts validation of point-of-need coronavirus test

Mologic starts validation of point-of-need coronavirus test

March 26, 2020 By Sean Whooley

Mologic announced today that it initiated early validation of point-of-need COVID-19 diagnostic tests with two United Kingdom-based universities.

The Bedfordshire, U.K.-based company is initiating its tests with the Liverpool School of Tropical Medicine and St. George’s University London, according to a news release. The accelerated development of the test is a product of funding from U.K. Aid, as the government is putting £46 million ($55.4 million) toward coronavirus prevention and research.

Mologic said in the news release that its early prototypes of antibody tests made it possible to begin a process of optimization as laboratories around the world will evaluate the different prototypes and assess their performance. The company said the technology will be shipped to global validation partners including the Institut Pasteur de Dakar (Senegal), La Jolla Institute for Immunology (U.S.), the Wuhan Institute of Virology (China), the University of Malaya (Malaysia), the Institute for Health Science Research Germans Trias I Pujol (Spain), and the Oswaldo Cruz Foundation (Brazil). 

The diagnostic test is designed for users to check for exposure to the virus at home, in the community or in a clinic, providing results within 10 minutes and eliminating the need for special training, electricity or a lab. Mologic said it will sell the test at a cost to low-income settings in an effort to ensure that affected countries have access to the kits during the global pandemic.

“Completion of the first prototypes is a significant step in Mologic’s development of a rapid diagnostic test for COVID-19 and we are proud of our team’s achievement in reaching this point so quickly while maintaining the most rigorous standards,” Mologic co-founder & chief scientific officer Paul Davis said in the release. “Diagnostics are a critical weapon in the fight against this pandemic and, once ready, this test will enable affordable, more accurate and earlier diagnosis of infection, limiting the spread of the disease.”

Mologic medical director Dr. Joe Fitchett added that there’s a need for decentralized diagnostics until a vaccine is ready or a medicine is proven to be effective. “Properly assessing new tests during an epidemic is a critical and necessary step to ensuring access to the technology. Mologic’s prototypes will now be subject to international validation, with leading labs across the world.” 

Filed Under: Diagnostics, Genomics/Molecular Diagnostics Tagged With: coronavirus, COVID-19, Mologic

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy